Pilaralisib analogue 25 mg | 99.46%
TargetMol
Pilaralisib analogue (XL147 analogue) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ.
More Information Supplier PagePilaralisib analogue
Search Results
Droxidopa 25 mg | Purity Not Available
TargetMol
Droxidopa is an orally available prodrug of norepinephrine that is used in the treatment of symptomatic orthostatic hypotension due to neurogenic causes of autonomic failure.
More Information Supplier PageDroxidopa
Droxidopa 10 mg | Purity Not Available
TargetMol
Droxidopa is an orally available prodrug of norepinephrine that is used in the treatment of symptomatic orthostatic hypotension due to neurogenic causes of autonomic failure.
More Information Supplier PageDroxidopa
Latanoprost 25 mg | Purity Not Available
TargetMol
Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect.
More Information Supplier PageLatanoprost
Latanoprost 2 mg | Purity Not Available
TargetMol
Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect.
More Information Supplier PageLatanoprost
PFK-015 200 mg | 99.70%
TargetMol
PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).
More Information Supplier PagePFK-015
PFK-015 100 mg | 99.70%
TargetMol
PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).
More Information Supplier PagePFK-015
Pilaralisib analogue 200 mg | 99.46%
TargetMol
Pilaralisib analogue (XL147 analogue) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ.
More Information Supplier PagePilaralisib analogue
Fimepinostat 25 mg | 99.23%
TargetMol
Fimepinostat (CUDC 907) is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan-histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many […]
More Information Supplier PageFimepinostat
Fimepinostat 2 mg | 99.23%
TargetMol
Fimepinostat (CUDC 907) is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan-histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many […]
More Information Supplier PageFimepinostat